SIOX News and Press, Sio Gene Therapies Inc. From 03/15/21

Company had $120.9 million of cash and cash equivalents as of March 12, 2021 Substantial increase in liquidity driven by equity investment from Suvretta Capital and sale of Arvelle shares Company estimates it is fully funded through major upcoming milestones for GM1 gene...

NEW YORK and RESEARCH TRIANGLE PARK, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company wi...

SIOX has promising results in its gene therapy programs. Not only is the Parkinson's disease program showing impressive results, but recent developments on the rare disease front are also very encouraging. I work through these developments and then turn to the company's valuation ...

Biotech Penny Stocks To Watch Right Now February closed out with a tumultuous week of trading in more than just penny stocks . Fears of inflation and uncertainty about the final stimulus plan triggered large sell-offs last week. Whether you were looking at small-caps or broader sect...

Gainers: [[SIOX]] +12.1%. [[OPTN]] +7.2%. [[BDSI]] +5.7%. [[SSP]] +4.9%. [[SPPI]] +4.9%.Losers: [[PCTI]] -6.5%. [[SVC]] -5.4%. [[GNFT]] -4.2%. [[NIU]] -3.4% [[CATB]] -2%. For further details see: NIU, SPPI, BDSI and SVC among after-hours movers

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company wil...

Sio Gene Therapies (SIOX): FQ3 GAAP EPS of -$0.20 beats by $0.09.cash and cash equivalents of $81M.Press Release For further details see: Sio Gene Therapies EPS beats by $0.09

- Company had $81 million of cash and cash equivalents as of December 31, 2020, and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway expected into the second calendar quarter of 2022 NEW YORK and RESEARCH TRIANG...

Sio Gene Therapies (SIOX) rallied 7.4% premarket on receiving $11.6M from the closing of the sale of Arvelle Therapeutics to Angelini Pharma.Under sale terms, additional payments to Sio Gene Therapies are expected over time, including a payment of ~$4.8M by mid-2021 u...

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that it has received...